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Winings, 2
Abstract:
The use of psychedelic medicine has been a part of society and the evolution of humanity since
the beginning of our existence. Throughout the years, these practices were integrated into
cultures around the world throughout the years, as societal structures promoted traditional
practices reflective of ritual and custom. One such practice that survived the test of time is the
use of psychoactive substances to promote mental states that put the user in touch with spiritual
ancestors as well as with the subtleties of the world around them. These practices included tribal
usage in indigenous cultures from Africa, the Americas, parts of Europe and other geographical
areas where psychoactive substances naturally occur. The reality of these emerging traditions
across the world provides a directive towards one key point: humans have valued the ability to
transcend normal mental states through the use of chemical substances ranging from a variety of
plant and animal sources. Reflecting on the value of these transcendental experiences, the
incorporation of these practices in culture has withstood the test of time. Today, the use of
psychoactive substances is re-emerging as a formidable source of treatment for mental disorders
that have been considered incurable since their discovery, creating a pathway for incorporating
psychedelics yet again into society and culture in a meaningful way. This review will investigate
past and current research regarding psychedelics to project the transitions that may occur as these
substances become more mainstream. Additionally, this revitalization raises a vital question that
is the focus of this study: How can the current psychedelic movement avoid the clinically sterile
history to promote a culturally inclusive approach towards the future of mental health treatment?
Through the integration of Traditional Ecological Knowledge (TEK) into the formulation of
psychedelic-assisted therapy, it remains possible to weave tradition-based ways of life into
therapeutic modalities that leverage psychedelics. Finally, by involving more diverse individuals
in the formulation of psychedelic-assisted therapies, the field transitions from supporting a
traditionally white system of mental health care to a culturally diverse health system that may
provide a more culturally competent approach for patients. In developing these idiographic
therapies, we support a system of health that works to de-stigmatize a long-standing history of
abuse and discrimination and a society that accounts for a culturally diverse experience in the
diagnosis of disorder.
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Introduction
Psychoactive substances are an object of today's reality that went from heavy
stigmatization to much greater normalization in a matter of 20-30 years. Just this past week I was
home visiting family after a winter in Denver, Colorado when my mother approached me to ask,
“Son, what is micro-dosing?” Admittedly, I was a bit taken off guard, thinking her question
could be related to the recent decriminalization of psilocybin in Denver, but soon realized the
inquiry was more so a testament to the emerging mainstream nature of psychedelics and their
recognized therapeutic benefits. I happily explained how microdosing involved taking a
less-than-psychoactive dose of psychedelic chemicals such as acid or the aforementioned
psilocybin. When questioned about the potential therapeutic benefits of microdosing, I responded
with a grin paired with, “How would I know?” After reassuring her my expertise on these drugs
was born within the confines of this paper, I followed up with some quick yet remarkable facts
about various cognitive and emotional benefits such as heightened focus and decreased anxiety.
While one could assume mother's questions were additionally warranted given my topic
for this senior project, it was surprising to learn that a discussion between suburban parents on a
Facebook forum piqued her initial interest. In coming to discover my mom’s and similar parents’
increased interests regarding the world of psychedelics, I became more comfortable with the idea
this is a burgeoning realm of scientific study that can find its way into discussions of any
modern-day American family.
While it’s comforting to know that what you find interesting is of interest to others, this is
not the sole reason I sought out to study this realm of research; rather, I am intrigued by the past,
present and future state of psychedelic use and surrounding context including therapeutic
applications. The indigenous history of psychoactive substance use has roots all around the world
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deep into chapters of different cultural history books. Yet, the recent history of psychedelics
within the modern era has been erratic and surrounded with mysticism. Following the
synthesization of LSD, isolation of the active chemical in mushrooms (psilocybin), and mass
distribution of these chemicals, an important chapter of history seems to be erased away from the
everyday mind. Various questions that arise from my analysis of this anthropology regarding
psychedelics are around why these drugs disappeared for so long, and why is society now
choosing to give them another chance? The criminalization of psychedelics provides a veil of
misunderstanding regarding the progress in the emergence and evolution of these compounds,
which warrants rectification. While psychedelic substances became criminalized in the US and
many subsequent countries following drug act policies in the 1970s, research around these
compounds did not stop altogether. In these times, clandestine chemists and underground
research marked a transition in the exploration of this science, as it truly became the
responsibility of a scientist to be a subject within their own research.
There may come a time where psychedelic researchers, coined “psychonauts,” such as
Alexander Shulgin, Stanislav Graf, Paul Stamets, among many others, could rather prove to be
the “Einstein’s” of psychological research involving consciousness and the implications of the
therapeutic and cognitive potentials associated with psychedelics. While the world of physical
health is being refined with modern technology, the world of mental health follows with a
shortened history that necessitates any advance that may be presented. This lack of history – and
consequently, less refined science – surrounding mental health presents a wonderful opportunity
for pivotal scientific advances in the field.
In recent years, the revitalization of psychedelic science is due largely to the presentation
of these drugs as a viable treatment for a range of clinical conditions. Insight into the application
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of these drugs seems to be a result of not only past research but as well underground reports
regarding the efficacy of these forms of drugs within a range of applications. While I will
specifically focus on LSD and psilocybin throughout this paper, it is important to note these are
not the only formidable psychedelics being used for treatment in the clinical setting.
Ketamine, Ayahuasca, Ibogaine, and MDMA are others among the wave of psychoactive
chemicals being applied to a variety of clinical patients investigating the use of psychedelics.
While Ketamine and MDMA clinics are becoming more prevalent in cities like New York and
San Francisco, Ayahuasca ceremonies remain underground in much of the United States but are a
main attraction in countries such as Peru and Mexico. With psychedelics on the rise in a variety
of environments for a diverse array of applications, these substances are once again on the come
up to reaching peak societal involvement.
Though there are a variety of different psychedelic drugs in use today, this project sought
primarily to understand the drugs used in clinical trials. The most prominent of the classical
psychedelics in trials today is psilocybin, the active ingredient found in magic mushrooms. To
answer questions like my mother’s in addition to my own, this review investigates the various
ways psychoactive substances have evolved along with society over time. Over the course of
exploring this history, the aim is to better understand the use of these drugs by both clinicians
and underground researchers within the realm of psychedelic research. In gaining a more
thorough comprehension of the history of these drugs, I hope to provide a detailed projection
regarding the future of this field and how psychedelics could change the cultural conversation
surrounding mental health treatment.
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Decriminalization of Psychedelics in Oakland, Denver, Santa Cruz, Oregon and Washington
D.C.
While psychedelics remained heavily criminalized for a considerable period following
the 1970s, recent investigation into the therapeutic potentials of various psychoactive compounds
has yielded a new wave of psychedelic research. Pairing substances like ketamine and psilocybin
with assisted therapy for disorders such as anxiety, depression, PTSD and substance abuse
disorders has produced a following of individuals advocating for the therapeutic efficacy of these
substances (Lyons-Carhart Harris, 2018; Grob et al., 2011; Anderson et al., 2020). Yet, as
cannabis decriminalization and legalization have shown us, the pathway from illicit to medically
approved therapeutic is filled with various FDA and DEA-enforced processes; these include
clinical trials, licensing, revised legislature and substance reclassification. Additionally, similar
to the cannabis decriminalization movement, changes in laws concerning psychedelics are only
occurring at local and state levels. Therefore, the legalization and reclassification of psychedelics
face not only state restrictions but also federal regulations.
Decriminalization efforts surrounding psychedelic substances began with the cities of
Oakland, Denver, and Washington D.C., igniting more significant movements across Oregon,
Washington State and California. The earlier legal changes allowed for possession of psilocybin
without criminal repercussion for both recreational and medical users in these regions, who can
now experience the substance without interference from local officials. While the medical
potential of these drugs presents a strong case in support of further legalization and
decriminalization, this consideration is just one of many within the realm of psychedelics. In the
shadow of the medical push for legalization remains the equally important arguments from

Winings, 7
religion, neuroscience, and identity politics that play a role in the formulation in the laws
regarding psychs (Marlan, 2019).
Smaller movements of 2019 acted as catalysts for statewide decriminalization in 2020;
notably, Oregon's 109 and 110 ballot measures legalized the distribution and manufacturing of
psilocybin, while also decriminalizing all substances. Following suit in 2021, California has
proposed bill SB 519 to decriminalize psychedelics, which has already passed the Senate health
committee (Roberts, 2021). These movements have shown that policies surrounding
psychedelics are changing not only for a medical audience but also for recreational users. The
issue with legalization strictly for therapeutic purposes then provides a confusing line of illicit
vs. legal use surrounding psychedelics, which already has a difficult barrier for access (Noorani,
2019). It seems more extensive efforts to completely decriminalize all substances, arguably
allowing safe possession for both medical and recreational patients, promote a clearer route
towards better public health treatment.
Interestingly, due to the nature of the clinical process towards legalization, a bulk of the
legwork done with these substances has been directly supported by the pharmaceutical industry.
While MAPS, the Multidisciplinary Association for Psychedelic Studies, has tried to sustain a
substantial role in advising clinical trials and weighing in on psychedelic legalization, the
financial promise of psilocybin therapy remains a focal point to pharmaceutical investors. A
valid fear surrounding the medicalization of psychedelics is rooted in the clinical environment
becoming too far removed from the tradition this form of treatment stems from; additionally,
criminalizing use by recreational participants muddies the waters. In focusing solely on what
psychedelics can do for us medically, we lose sight that these drugs can elicit strong spiritual,
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cognitive, emotional and religious changes that may be just as impactful as the therapeutic
healing that can be experienced.
In light of the recent decriminalization of these substances, it is essential to question how
social changes stemming from legislative changes allowing increased use may induce changes in
our society as a whole. As we dive deeper into the various potentialities of these substances as
additional patients and users share their experiences, the discussion surrounding psychedelics is
poised to develop and evolve. Will we learn to integrate these substances into our diverse ways
of life, learning from other cultures from which these practices stem? Will the integration of
psychedelic substances change how we approach mental health and public health not only on a
local level but also on national and global scales? To downsize the relevance these substances
have on modern society is to undermine these drugs’ influences on various influential social and
political figures of our lifetimes. In exploring the role these drugs had in the past and comparing
this influence to current and future movements in the psychedelics landscape, I hope to present a
shifting perspective surrounding mind-altering drugs as we transcend the bounds of flawed drug
policies into a more awakened society.
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Section 1: Epistemology of Psychedelics
Chapter 1. Psychedelic Use in the United States: The Clinical History of LSD
The Origins of LSD
LSD, also known as lysergic acid diethylamide, is considered one of the main
psychedelics that sparked the psychedelic revolution, oftentimes leading individuals to refer to
acid as a classical hallucinogen. LSD, also known as L, Lucy, acid, tabs, and many other street
names, has been used in clinical practice since the 1950s, with recreational use becoming more
prevalent throughout the 1960s.
The discovery of the chemical basis for LSD was first stumbled upon in Switzerland by
the Sandoz pharmaceutical researcher Arthur Stoll. At the time, Stoll was working to reduce the
toxicity in ergot, an agent whose postpartum use and hallucinogenic properties stem back to
Ancient Greek times. Stoll’s work with ergot helped to isolate the active compound responsible
for the production of LSD by defining the starting point: lysergic acid. Building upon the
foundation developed by Stoll, Albert Hoffman, another Sandoz researcher, synthesized the first
batch of LSD by combining reacting lysergic acid with diethylamine to produce LSD-25.
Though the LSD was officially created at this time, its subjective effects went unknown for
another five years, until 1943. On April 19th, 1943, Hoffman again synthesized LSD-25 and
accidentally came into contact with the substance, on what came to be known as Biking Day
(Shroder, 2014). Through the accidental exposure to LSD and its subsequent effects, Hoffman
unknowingly opened the world’s eyes to the possibility of synthetically produced agents that
produce a profound psychedelic experience historically only attributed to certain psychoactive
plants and fungi at the time.
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Hoffman’s work led to an extensive exploration into the use of LSD, with a wide variety
of animal subjects tested including mice, spiders, cats, chimpanzees; eventual
self-experimentation was performed by Hoffman and his close associates. In addition to the
discovery of LSD and its subjective effects, a notable initial finding by Hoffman was the
associated lethal and effective doses for LSD. Hoffman found, “None of the animals in the tests
seemed to suffer acute harm at the active dose, and the lethal dose was a hundred times higher
than what was necessary for psychic effect, leaving a wide safety margin” (Freeman & Chandler,
2020). With caution to the extreme potency and associated effects of LSD, LSD use in
experimentation and clinical practice exploded in 1947 as Sandoz laborites began to distribute
LSD as Delysid worldwide to various research institutes for use in psychiatric experiments.
(Hoffman, 1980 as cited in Freeman & Chandler, 2020)
The Spread of LSD: Experimentation, Clinical Use, and Recreation
Following its distribution, LSD became used in a variety of ways, from experimentation
in mind control by the US government, to clinical treatment for various mental disorders, to
social circles and experiments in university settings. Negative uses of this substance in the
pre-prohibition era have been connected to testing on unknowledgeable subjects, administering
extreme doses, and testing on mentally incapacitated patients.
After obtaining LSD, the CIA began testing unknowing patients with large doses of LSD
coupled with interrogative practices to explore these drugs’ potential in interrogations and torture
(Freeman & Chandler, 2020). In these experiments known as part of “Project MK-Ultra,” many
subjects were released without the ethical debriefing processes in place today; others were
contracted to participate in these questionable studies without the ability to fully consent to the
treatment they were about to receive. The outcomes of these trials are still unknown but can be
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viewed as an integral contribution to the mass hysteria surrounding the safety of psychedelics
that persists today.
Additionally, negative studies attributing to the literature on psychedelics can be credited
to experimental research done in the 1960s by researcher R. G. Smart and associates on the use
of LSD for alcoholism. While their study was designed in light of other substance abuse studies
involving psychedelics, it lacked attention to drug potency and the clinical design necessary to
promote a therapeutic environment. Participants were dosed with 800ug, an extremely high dose
for even the most experienced psychonaut (standard therapeutic doses start at 25µg), while also
being interrogated regarding their subjective state (Smart et al., 1966). While this study
concluded this treatment as a failure, the researchers noted facilitators and the facility might have
contributed to the discrepancies between this study and previous ones (Smart et al., 1966).
Additional studies that failed to report significant therapeutic effects using LSD included those
examining LSD for individuals with psychotic disorders such as schizophrenia. While these
studies lacked the significant positive effects associated with other trials on neurotic disorders, it
is important to note these treatments were conducted without the assisted forms of psychotherapy
we utilize in clinical trials today, as most patients were left to deal with their own reactions
(Rucker et al., 2018). Additionally, the basis for understanding mental disorders in the 1950s was
much more narrow than today, so individuals diagnosed with schizophrenia may have been
experiencing many different issues that could fall into another scope of understanding as well as
alternative treatment paradigm by today’s standards.
The adverse reports following experimental studies such as Smart and associates and the
CIA’s Project MK-Ultra created amplified concern regarding psychedelic substances and their
potentiality for acute harm stemming from psychotic states and associated behaviors. While
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these reports worked to perpetuate negative stereotypes associated with LSD, there was
simultaneous work being done by researchers in the realm of treating other neurotic disorders,
including depression, OCD, and substance abuse disorders that showed promising results.
Recreationally, as LSD also became available to street users, a shift in social perception around
the use of the substance and its place in the context of the social realm began to occur.
In the time period from 1950 to the late 1960s, there were thousands of psychedelic trials
being run in various settings throughout the world to investigate the potentiality and positive
applications of LSD-assisted therapy. The two forms of therapy that became central to using
these drugs in treatment became defined as psycholitic and psychedelic-assisted therapy.
Psycholitic therapy required patients to draw and focus upon childhood events to engage the
unconscious, whereas psychedelic-assisted therapy included higher doses of LSD coupled with
doctors to provide support throughout the experience but without the guidance associated with
psycholitic therapy (Freeman & Chandler, 2020). These practices were enacted in various
experiments investigating a range of symptoms, with one of the most notable trials occurring in
the United States at the Spring Grove State Hospital and Maryland Psychiatric Research Center.
This experiment included approximately 234 patients with a range of non-psychotic disorders
such as anxiety, depression, personality, and addiction. Following the administration of
psychedelics, without any assisting psychotherapy, 197 (81.1%) of the 243 patients reported that
their condition had improved to some degree with only 2.1% of the population reporting that the
treatment had worsened their state (Rucker et al., 2018). Other studies ran simultaneously in
various other regions reported similar successes across different participant pools, with
improvements or remissions of symptoms noted in roughly 70% or more of participants across
many studies.
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Meanwhile, clinicians worked to investigate and develop empirical support for the use of
psychedelic medicine and notable societal figures came forward as advocates for the use of LSD.
Some figureheads that may come to mind could include Einstein, the Grateful Dead or the
Beatles; yet, the most historically notable individuals advocating for LSD use include Ram Dass
(born Richard Alpert), Dr. Timothy Leary, and Owsley Stanley. Ramdas and Leary were both
renowned psychologists in their field and supported the use of LSD in clinical settings as well as
within daily life, with Leary coining the famous phrase, “turn on, tune in and drop out” (Leary,
2008). Much of the hippy counter-culture that ensued throughout the 1960s is often attributed to
figures such as Leary and Ramdas. Still, even these figures renounced much of the cultural
appropriation occurring at the time; they sought to awaken individual’s potentiality rather than
make them reliant upon a dissociated way of life. The recreational proliferation of these
substances can be accredited to clandestine chemists seeking to synthesize LSD in the same form
developed by Hoffman. Among such chemists was Owsley Stanley, who was able to
mass-produce and distribute LSD. Owsley Stanley contributed to not only the spread of LSD but
also to the integration of the substance into music and culture in the Bay Area of California.
Stanley worked closely with various social figures in the area, hosting concerts coined as “trip
tests” in which mass groups of people would take LSD in a musical or performance setting. This
promotion of combining culture and psychoactive substances developed into the idea that we
know today as the counterculture and the hippie movements of the 1960s.
In contextualizing the counterculture movement into our understanding of psychedelics
today, this culture drew much of its origin from African American and Native American cultures,
ultimately leading to their criminalization and stigmatization. While the hippie movement was
seen as a force for social change, defined by using or “dropping” acid, traveling, and leaning into
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greater actualization of the self, this came at the cost of demonizing the use of psychedelic
substances and the cultures that initially embraced and embodied use of psychedelic substances.
Rather than acknowledging the indigenous origins of the hippie movement, the white hippie
narrative projected a label of white understanding without acknowledging the history of
colonialism and racial injustice that subjugated indigenous cultures. The fallout of this
movement resulted in a fervent anti-hippie counterculture that undermined the movement’s
repercussions in perpetuating racial stereotypes (George et al., 2020). The resulting drug
prohibition in response to the counterculture was largely reared at the Black, Hispanic, and
Native communities. These perceived “hippie” integrated cultures were targeted while white
individuals reaped the benefits of psychedelic-induced transcendental experiences without
recourse. The reparations needed to acknowledge the damage done to these cultures are
immeasurable, financially speaking. Therefore, as these drugs reemerge in our modern society, it
is essential to ask how we may include different cultures in the discussion on the administration
as well as the availability of psychedelic substances for various ethnic communities.
Tripping Out: Physiological and Subjective Responses to LSD-25
LSD can be taken in a variety of ways, from injections, through touch by glands in the
skin, and most commonly through oral sublingual administration. Frequently, users will take
LSD in the form of a tab that can range anywhere from 125ug-250ug for one complete square, or
by dropper, taking the substance and placing it on or under the tongue for approximately 10-15
minutes. Upon taking the substance, LSD is completely absorbed by the digestive tract,
distributing the chemical throughout the body through plasma binding to blood proteins (Passie
et al., 2008). LSD intake produces a range of sympathomimetic responses in the body that start
within 30-45 minutes and peak anywhere from 1.5-3 hours, depending on an individual’s
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stomach contents and physical makeup. Observed autonomic responses resulting from the
consumption of LSD include increases in blood pressure, heart rate, temperature and pupil size.
Other related physiological, autonomic changes include headache, nausea, imbalance, and
feelings of exhaustion (Liechti, 2017). While these changes in body state have been noted, the
overall responses do not pose acute harm to the individual as long as they do not accentuate
pre-existing conditions. To date, there have been no recorded deaths related to autonomic
responses induced by LSD (Passie et al., 2008). The duration of action of this drug lasts about 12
hours with LSD being completely metabolized 48-72 hours following initial consumption of the
substance. One of the more interesting components that warrants further research is changes in
brain connectivity and heightened brain entropy in response to LSD. In preliminary studies, it
seems LSD increases brain functionality in multiple regions, decreasing the integrity of brain
networks by providing new networks of functional activity by which the brain processes and
integrates information (Carhart-Harris et al., 2016).
While the previously listed physiological responses do not provide much room for
concern in regard to toxicity, the related subjective effects have been marked as the most
dangerous, as well as the therapeutic component of this drug. The biggest room for apprehension
regarding this drug’s subjective response is psychosis and sustained psychosis resulting from
consumption, defined as hallucinogen persisting perception disorder (HPPD). This condition can
consist of brief trip flashbacks in which the user experiences anxious and dissociated states, or a
continuous psychosis that causes functional impairment and anxiety for months to years (Halpern
et al., 2018). While cases of HPPD are rare, they have been noted in scientific literature
throughout the years. The prevalence of this occurrence may provide context for the hysteria that
perpetuates the fear behind LSD and the possibility of losing one’s mind. While cases of HPPD
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have been recorded, the occurrences are far and few between, with anxiety being a more
commonly reported negative effect associated with the use of this substance.
The subjective positive effects of LSD have been reported in various past and current
research. The most common effects of this psychedelic are changes in audio-visual synesthesia,
distortions in imagery, and finally, an experience of a blissful state, sometimes referred to as
oceanic boundlessness (Liechti, 2017). Users often report kaleidoscope-like shifts in visual
perception and changes in how the self is perceived when looking at one’s own image in a
reflective surface. Also, users report a range of symptoms such as positive fixation on certain
objects, random bouts of joy, uncontrollable laughing and tears of joy. These empathogenic
feelings often mark the euphoric sense of happiness seen in subjects and the reports these same
users have about their unbreakable connection with others. This increased connectivity is one of
the more significant attributes of LSD in relation to therapy as it provides a possible route to an
increased therapeutic alliance between patient and practitioner. This alliance could prove key in
providing a deeper investigation into the components of experience and trauma that may not be
reachable in one regular counseling session with a therapist.
Ego dissolution is a vital component in the waning perceptions of the self and reality as a
whole throughout this experience. Ego effects can be some of the most profound qualities of
LSD use; to describe this so-called ego dissolution, it is easiest to observe the process in its
simplest form, as each perception of self is also relative to experience. Ego dissolution is a
departure from the self in which the lines of the subject’s narrative erode away, leaving reality
for simply what is. The individual is then left in space as an object within reality connected to
everything in the universe and no longer a subject of their own cinematic experience within that
reality.
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Mechanisms of Action: The Neurochemical Effects of LSD-25
Many stories exist regarding the effects LSD can have on both the mental and physical
state, from visual and auditory shifts, to sweating, tremors and dilated pupils. What about LSD
controls the multitude of changes we observe? Which neurological pathways may provide some
context regarding how LSD initiates this variety of responses? The indole base of carbon,
hydrogen and nitrogen is a key structure found in LSD that mimics the same composition of the
neurotransmitter serotonin, providing some insight into the mechanism of action by which LSD
promotes physiological and affective response. Before going too deep into the possible ways
LSD acts upon the human body, it is important to note that research and understanding around
this drug’s pharmacology and pharmacokinetics are still being investigated and examined today.
That said, there is no resounding conclusion regarding the exact way this substance acts upon our
system.
As previously stated, LSD mimics the structure of serotonin molecules, leading
researchers to believe LSD binds to receptors within the serotonin pathway. Specifically, LSD
acts as an agonist upon the serotonin 5-HT1A, 5-HT2A, Dopamine D2 and a2 adrenergic receptors
(Liechti, 2017), promoting stimulation at these receptor sites. This draws an interesting parallel
to our understanding of the use of LSD for treatment for depression and anxiety, as these
conditions result from depressed receptor activity in the 5-HT receptor regions and poor
neurotransmission of serotonin. These neurochemical issues are typically treated with
antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and monoamine oxidase
inhibitors (MAOIs) that promote better signaling and neurotransmission in these regions. Yet, the
side effects and questions related to the placebo effects of antidepressants draw into question
whether these substances are a viable source of treatment. The immediate impact of LSD on
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these regions provide an expedited means of treatment that is unmatched by other forms of
medication. Notably, follow-ups on patients undergoing LSD therapy after 6-12 months
following treatment were marked as positive, referencing the effects of the psychedelic-assisted
therapy as life-changing and resounding (Fuentes, 2020). These positive long-term outcomes
allow us to consider how a couple of LSD treatment sessions could provide a viable response to
depressive disorders just as effective as administering anti-depressant substances and prolonged
therapy sessions, which are often costly and sometimes ineffective.
Another notable effect of LSD is the activation of glutamate systems, resulting in
increased glutamatergic activity, which directly affects prefrontal cortex functionality. This
component of LSD reactivity may provide insight into how this substance reacts to promote
change in individuals undergoing this form of therapy for substance abuse. Increased glutamate
activity from LSD may allow a more heightened awareness stemming from reward pathways,
specifically the glutamate pathway as, “the role of glutamate transmission in two complex
heterogeneous brain regions, namely the nucleus accumbens (NAcc) and the ventral tegmental
area (VTA), mediate the rewarding effects of drugs of abuse” (D’Souza pg. 1, 2015). With the
understanding that LSD acts upon key components of this pathway, it is reasonable to suggest
marked changes in the user’s perception of reward in relation to objects of trauma or abuse will
occur; the exact shift in perception is likely to be influenced greatly by an individual’s unique
experience and is an excellent question of exploration for future research.
While there seems to be compounding evidence for the use and efficacy of LSD therapy
in non-psychotic disorders, other portions of scientific literature appear to negate the use of this
substance for more severe psychotic disorders. Reflecting on LSD treatment’s efficacy for
schizophrenic patients, our modern understanding of schizophrenia does not lend itself to
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suggesting LSD as a viable way to induce a therapeutic neurochemical change for these patients.
Oftentimes, schizophrenic patients deal with malfunctions of the 5-HT receptors, leading to
over-agonized or antagonized signaling in this region, causing the array of symptoms associated
with schizophrenia; these range from hallucinations (positive effect) to catatonic states (negative
effect). Therefore, using an agonist such as LSD on someone with a possibly malfunctioning
NDMA region may explain the lack of efficacy for this treatment in psychotic disorders. It seems
likely that agonizing the 5-HT1 receptor may promote more of the effects associated with
schizophrenia, specifically psychotic episodes stemming from hallucinations. In addition to 5-HT
agonism, the increased glutamate activity component of LSD may accentuate the effects of
schizophrenia, as research in NDMA blockades has implicated that increased cortical glutamate
molecules may be a key mechanism responsible for schizophrenic related psychosis (Stone,
2011). Therefore, LSD is observed to negatively impact the related effects associated with 5-HT
receptors in people with schizophrenia and may also affect the cognitive states controlled by
glutamine activity.
While LSD may not apply to treating schizophrenia, there are many other applications
this classical psychedelic drug may be used for. Established evidence has shown this drug may
be beneficial for issues related to the 5-HT region malfunctioning and serotonin imbalances
prominent in disorders such as anxiety and depression. In learning more about the neurochemical
mechanisms responsible for profound changes witnessed with LSD administration, we can come
to know the exact ways in which this drug may be used to achieve the highest level of
therapeutic potential.
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Chapter 2. Indigenous Origins: Magic Mushrooms and Shamanic Ceremonies
Where Did Psilocybin Use Originate?
Psilocybin and Psilocin are the active compounds responsible for the psychedelic
properties of most psychoactive mushrooms. The emergence of psychoactive fungi is difficult to
pinpoint, but use of these substances is dated to prehistoric times. Some hypotheses even suggest
psychoactive mushrooms played a pivotal role in the evolution of human consciousness. These
theories are based on the idea that increased visual acuity and sensation stemming from
mushrooms provided an evolutionary advantage for those under the influence. According to
these hypotheses, these advantages allowed for more enhanced hunting capabilities and thus
better food availability leading to increased brain development (McKenna, 1993).
While it is unclear when humans consumed the first “magic” mushrooms, it is evident the
incorporation of psychedelic mushrooms became integral to many cultures across different
geographical locations. For example, in parts of Europe, the Muscaria species of mushrooms
were consumed to help cope with the climate and for their medicinal properties (Nyberg, 1992).
The mushroom was revered by Mayan and Aztec culture as a bridge to nature and the spiritual
realm, with the native people referring to the fungi as Teonanacatl, or flesh of the Gods
(Carod-Artal, 2015). Over time these substances became pivotal in defining religious and
cultural systems in a variety of locations.
The visionary properties of psychedelic mushrooms are among the many benefits this
substance was used for in the indigenous context. Other therapeutic benefits included relief from
a range of physical and mental health problems such as gastrointestinal issues, inflammation,
depression, anxiety, addiction and more. The allure of these benefits came to the public eye in
the late 1950s and 1960s following Robert Gordon Wasson's reports of his experiences with the
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mystical qualities of the magic mushrooms (Wasson, 1957). After multiple reports in reputable
journals and media features, including the front page of TIME magazine, Wasson’s reports shed
light on a hidden gem within the indigenous tradition of the Mazatec culture (Wasson, 1958).
Like any other prized possession, the qualities of the sacred mushroom became sought
after by people far and wide, bringing heavy foot traffic to a once-hidden and sacred community
in rural Mexico. Maria Sabina, the curandera that administered Wasson’s ceremony, became
ostracized by various parties of the region due to all the foreigners coming to the community for
the sacred ritual. While Wasson may have revered the ceremony and had the best of intentions in
bringing the psychedelic mushroom to the public eye, the downstream effects led to the
disruption of a sacred culture and exploitation of this therapeutic resource. This staunchly echoes
themes similar to the downfall effects that followed the counterculture movement and LSD in a
way that must be noted and not repeated in future psychedelic revivals.
The Harvard Psilocybin Experiments: Concord Prison and Marsh Chapel
Following an introduction into the public space in the 1950s and 1960s, psilocybin and
other psychedelics became hot topics of interest in the realms of research. Researchers began by
testing the effects of various psychedelic drugs in the lab environment, followed by more
thorough investigations in applying these substances as medicine for a variety of physical and
mental health disorders. It’s interesting to consider that almost 60 years ago, researchers viewed
these substances with possible therapeutic benefits that we are just now as a society coming to
accept as legitimate.
Two notable experiments defined early psychedelic research of psilocybin; these were led
by two aforementioned formidable psychonauts, Timothy Leary and Ram Dass. Leary and
associates conducted the Concord Prison Experiment to determine if administering psilocybin to
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inmates could reduce recidivism following release. While noting the sessions’ positive impact in
an acute setting on the subjects, it was clear the original hypothesis that these drugs could reduce
recidivism was lacking the comprehensive treatment plan and follow-up to incorporate the
experience into daily life (Doblin, 1998). Through the Concord Experiment, it became clear that
psilocybin could cause mental state changes in the acute setting but required some form of
residual therapy or ceremonial practice to induce a lasting psychological impact.
While the Concord experiment marked an initial step towards therapeutically applying
psychedelics, there remained myriad research opportunities regarding the properties and uses of
these substances. Pursuit of evaluating these properties sprung another experiment named the
Marsh Chapel Experiment, an extension of Leary’s project examining the mystical qualities of
psilocybin and their effects on spiritual experiences. In this experiment, a group of theology
students were either given a niacin pill (placebo control) or a psilocybin-containing pill and were
observed and questioned following the experience. Results showed each individual who
participated had a spiritual experience, with many within the psilocybin group citing heightened
spiritual experiences with God (Shipley, 2014). Following this experiment, compounding
evidence began to support the idea that these drugs could truly incite spiritual experiences with
profound effects.
Experiments such as these were rampant throughout the 1960s, with both legally
recognized and underground researchers exploring the various benefits psilocybin mushrooms
could offer. Following this era, the same drug enforcement administration that eliminated much
of the LSD movement also began to conceal and eradicate research on psilocybin-containing
mushrooms. Much of the underground research work conducted between 1970-1990 was led by
figures including Steven Pollock, Paul Stamets, and Alan Watts. These investigators spent their

Winings, 23
time examining the wide array of psilocybin-containing mushrooms worldwide, using their
taxonomy and mycology skills to bring scientific light to a world previously unknown to many.
Pollock is viewed as a founding father of defining the agricultural substrates required to produce
highly potent mushrooms on an industrial scale while also discovering new species of
mushrooms such as Psilocybe Tampanensis, coined “the philosopher's stone” (Morris, 2011).
The downstream effects of Pollock’s work can still be felt today as he helped develop the
methodology of procuring spores and mycelial colonies for distribution and home growing that
enabled many to toe the line of legality while still producing psychedelic medicine for personal
use. Stamets, alongside Pollock for much of his career, is now one of the leading mycologists in
reference to both psilocybin-containing mushrooms and other medicinal mushrooms – those
without psychedelic properties – that can be supplemented into anyone’s diet. Stamet’s influence
stems far beyond hallucinogenic compounds to show how a deeper taxonomic understanding of
fungi can help alleviate various problems ranging from supporting mental health to solving
world hunger through mass production of consumable fungi. Also working in periods similar to
Stamets and Pollock, Watts was an essential figure for defining how spiritual experiences related
to psychedelics may be explained to a Western audience through Eastern teaching. Together,
these individuals are primarily responsible for the scientific revival of these substances by their
methodological approaches of investigation that their antecedent peers of the 1960s did not as
strictly observe. Many accredit these underground psychonauts’ strict adherence to scientific
methodology with helping to introduce the current psychedelic renaissance occurring throughout
the world today.
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The Mushroom Trip: Physiological and Subjective Effects of Psilocybin
The ingredient in magic mushrooms responsible for hallucinogenic effects is psilocybin.
In a recreational setting, users may consume small amounts such as .1-.5g, which would be
therapeutically defined as a microdose. A more experienced user may consume up to 3-5gs,
which would be considered a “heroic dose.” The toxin within the mushroom’s fruiting body
works by releasing upon consumption, often being broken down by acids in the stomach and the
mouth. Psilocybin is then converted from its inactive form into the active compound psilocin by
enzymes along the digestive tract. In dissolving into the active ingredient psilocin, the toxin
becomes lipid-soluble, allowing the psilocin to be actively distributed throughout the body
through the bloodstream (Bauer, 2020).
The dose-dependent effects of the psilocin begin to act within 20 minutes, with effects
steadily elevating to the peak of the experience at around 180 minutes. During the time period
20-180 minutes post-dosing, psilocybin is actively converted to psilocin, inciting the psychedelic
state as psilocin accumulates and psilocybin depletes. Throughout this process, the most notable
physiological effects become prevalent with increases in cardiovascular measures, including
blood pressure and heart rate, in addition to increases in body conductance, a measure of
peripheral signals associated with emotions and behavior. Other noted physiological effects are
dilation of pupils, with subjects reporting an increased visual field and – in some cases – even
night vision. Lastly, psilocin has activating effects on the digestive system, with many
individuals reporting nausea and interruptions in their gastrointestinal systems. In the traditional
setting, irregular digestion is an opportunity for spiritual purging, a moment in which the
partaker in ceremony can rid the body and soul of perceived evils and toxins that may be
accentuating the negative feelings (Lane, 2018). On a technical level, the interaction of psilocin
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with stomach enzymes may result in an increased acidic environment that induces the nauseous
and gaseous state.
While the physiological effects are specific to the activation of the body’s sympathetic
systems, subjective effects are related to the activation of serotonergic receptor sites responsible
for the emotional and perceptual responses that are the hallmark of the altered experience (Hasler
et al., 2004). Along the same timeline as the initiation of physiological effects, cognitive changes
begin to occur at around 20-40 minutes post-dosing, with peak changes in perception occurring
around 120-180 minutes. During this timeframe, the changes that ensue have been categorized
into four realms, with alterations occurring in the perceptual, cognitive, emotional, and ego
segments of our unconscious and conscious mind (Kargbo, 2020).
Perceptual changes include shifts in visions, colors, and conception of time and space.
Cognitive changes may also encompass expanded creativity, language expression, and
synesthetic qualities such as seeing taste as colors or feeling sounds. The next area of alteration –
changes in emotional state – is of particular interest to the potential therapeutic application, as
these drugs intensify emotional reactivity and put the user in touch with their emotions. Also,
uncontrollable bouts of euphoria and anxiety may occur, but these feelings can often be regulated
within the context of appropriate therapeutic care. The final unique attribute of this medicine, the
ego dissolution component, promises a heavy effect on destructive ruminative processes by
forcing the user to depart from existing notions of self. By removing one’s ego from the
equation, the subject is then forced to shift their perspective in a way that comes into observance
of the universe as a whole (Lane, 2018).
The physiological and subjective qualities of psilocybin-based psychedelics offer a light
of therapeutic possibility in applying this form of medicine towards treating mental disorders.

Winings, 26
While studies on healthy populations have highlighted various effects of psilocybin at
dose-dependent levels, current research seeks to examine how the results observed in healthy
populations may work on clinically affected populations. Notable therapeutic areas of
exploration and application include the potential treatment of depression, anxiety, and various
addictions. Further research may examine the efficacy of this form of treatment for these patient
populations as well as the mechanisms by which the therapy acts to impart changes in mental
states.
Mechanisms of Action: The Neurochemical effects of Psilocybin
Like other classical psychedelics, psilocybin acts by agonizing serotonin receptors,
specifically the 5-HT-2A region. This region is a hot spot of activation for many psychedelics
including LSD and DMT; therefore it makes sense that psilocybin, another serotonergic, would
affect the same region (Ly et al., 2018). This process of neuronal activation occurs after
psilocybin is consumed and actively converted to psilocin, which then acts upon the serotonin
pathways to incite a psychedelic reaction.
Once in the bloodstream, psilocin is actively distributed in the body, binding to serotonin
receptor sites throughout while still maintaining a high affinity for the 2A region. The psilocin
continually acts upon the body as psilocybin is converted to psilocin, thereby activating the
5-HT2A receptor to produce a hallucinatory experience. The binding process of psilocin
especially interests some researchers as it appears that upon binding, the psilocin drug molecule
alters its configuration to better activate the neuron. The observed changes in neural plasticity
have led some to believe that serotonergic psychedelics can increase neuronal networks. Due to
the malleable abilities of this molecule, psilocybin is categorized as a psychoplastogen, a
substance capable of promoting plasticity at receptor sites (Ly et al., 2018). The drug's ability to

Winings, 27
reintegrate and strengthen neuronal networks – as evidenced by increased dendrite density and
signaling – gives hope to the idea that psychedelics such as psilocybin could be used to repair
malfunctioning or damaged serotonin regions; these disrupted neuronal pathways are implicated
as root causes for disorders such as depression and anxiety. Therefore, in consideration of
positive correlations of this therapy, subjects experience life-changing emotional and perceptual
changes and significant reintegration of neuronal networks responsible for our daily affective
states.
While the serotonin region has received the bulk of interest regarding psilocybin’s
therapeutic potential, the Default Mode Network (DMN) provides another avenue of exploration
into the drug by highlighting the role the self plays in application of these psychedelic-assisted
therapies. The areas operating with the DMN to control much of our cognition are the Medial
Temporal Lobe (MTL) and the posterior cingulate, where the DMN is suspected to be housed.
The MTL acts as the relay center between the hemispheric networks of the posterior cingulate,
conferring messages to the DMN while also producing visual hallucinations in its own right
when stimulated (Lebedev et al., 2015). Relating neural mechanisms to the actual cognitive
changes that occur, researchers suspect when an individual undergoes an ego-dissolution
experience that the associated default network influencing that subjective perception erodes,
leaving reality in its truest form, or realest form as a philosophical realist may say. In decreasing
signaling to the DMN region through psilocybin’s modulation of the MTL, the subject is freed
from notions of self and is then able to observe life in a way that is ego-less or what some may
call boundless. Reflecting on how psilocybin affects neural networks in a diverse number of
ways adds evidence to the hypothesis that psychedelic-assisted therapy may be applicable for a
variety of clinically affected patients.
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Section 2: Use of Psychedelics in Practice in the New Millennium: The Clinical Setting
Chapter 4. Psilocybin Assisted Therapy for Treatment-Resistant Depression and Death
Anxiety in Cancer Patients
Comparing Psilocybin-Assisted Therapy and ECT for Treatment-Resistant Depression
As previously discussed, psilocybin and psilocin are the active compounds in psychedelic
mushrooms that produce the perspective-shifting and euphoric states associated with most
classical psychedelics. The chemical structure of these compounds in mushrooms mimics similar
tryptamine structures found in other psychedelics such as LSD and Ayahuasca.
Neurotransmission of these compounds emulates that similar to serotonin and thus produces
effects primarily upon serotonin receptors in the brain, classifying these substances as
serotonergic psychedelics. Given the neurochemical makeup of these drugs and early results of
clinical trials conducted between 1950-1970, psychedelics are poised to re-enter the current
landscape as a viable treatment for a variety of mental health disorders.
The potential use of psilocybin for mental health treatment spans a variety of realms,
from treatment for OCD, death-related anxiety, substance abuse disorders, depression and more.
As depression is becoming increasingly rampant in society today, it is vital to explore how the
use of psilocybin for treatment-resistant depression (TRD) compares to other methods of clinical
treatment; current therapies include SSRIs, MAOIs, and Electro-Convulsive Therapy (ECT), one
of the most formidable, last-line treatments for TRD. Specifically, practitioners must evaluate if
psilocybin-assisted psychotherapy is safer and more effective than ECT as an employed therapy
for TRD.
ECT is a form of treatment for TRD used since its inception in the early-mid 1900s. ECT
involves using electric shock to the brain to induce convulsive states, which in theory and
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therapeutic application for most patients help to decrease depressive symptoms. From its
beginnings, ECT has been marked as extremely effective in reducing depressive symptoms.
While there have been obvious successes in using this therapy, questions regarding the use of this
treatment in regard to ethics, side effects and impact of this form of therapy – both during
treatment and in long-term follow ups – on the patient have arisen. Ethically, ECT stirred much
controversy in the past due to its attempted use for conversion therapy when homosexuality was
deemed a mental illness. Additionally, ECT has received some negative publicity regarding
patient consent and whether all mentally ill patients can consent to this potentially traumatic
form of therapy. While there are important historical and ethical considerations regarding ECT,
the most questionable concern is related to ECT’s effects on cognitive function. Investigations
into the acute effects of ECT on TRD patients have found decreases in cognitive function,
specifically in frontal cortex regions responsible for critical thinking, coupled with issues
associated with short-term memory impairment (Rami-González et al., 2003). Additionally,
longitudinal studies examining the effects of this treatment and harmful side effects found these
acute symptoms persist beyond the retrograde amnesia occurring following treatment and
continue to produce short-term memory impairment up to 20 years following treatment
(Macqueen et al., 2007).
While ECT may be effective, its questionable harm to benefit ratio leaves room for
further improvement concerning effective treatments for TRD. In light of the need for less
invasive and more effective treatments for TRD, researchers have begun evaluating the possible
effectiveness of psilocybin-assisted psychotherapy to treat this disorder. This form of therapy
requires an extensive interview process to prepare both the clinician and the patient for medical
administration, followed by various health checks. The clinician uses both the idiographic and
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physical health information garnered from this interview to produce a composite of the patient’s
mindset (often referred to as “set”) in consideration to the intentions desired from the session of
psilocybin-assisted therapy. The patient and practitioner then proceed to craft an ideal treatment
setting, intended to induce comfort and relaxation and allow for a safe environment for the
individual processing. The medicine is then administered orally in solution. The clinician sits
with the patient, often under the supervision of another clinician, as the patient undergoes the
transformative process associated with these forms of drugs. The clinician may use information
from the interview to help the patient interpret their feelings and visuals and guide the patient to
dive deeper into traumatic events that may trigger TRD-related symptoms. The ego dissolution
and empathogenic properties of the administered drug produce a state of openness that allows the
patient to delve deeper into their understanding of these traumatic events, while also increasing
therapeutic alliance between patient and practitioner to promote more positive treatment
outcomes.
Producing shifts in perspectives around how these events affect one’s livelihood, the idea
is individuals can integrate their newfound understanding of past trauma in a healthy way that
promotes hope for a happier future. The reduction of symptoms following this treatment is
astonishing and extremely promising, with a remission rate of up to 70% of patients included in
studies, with minimal reported acute side effects and no substantial long-term side effects. In
fact, in longitudinal studies examining long-term outcomes of this treatment, patients have
marked their experiences with psilocybin assisted psychotherapy as life-changing and
transformative in the treatment of their depressive symptoms. Most of the persisting adversity
regarding this treatment can be dated back to drug propaganda pushed throughout drug reform
efforts initiated by the Nixon and Reagan administrations following both the counterculture
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movement and crack epidemic. Throughout legitimate clinical studies run to date, the object of
most concern is anxiety during treatment and increases of sympathomimetic symptoms, which
can be greatly mitigated by the presence and care of the practicing clinician administering the
treatment.
The cognitive effects of this drug-assisted treatment are some of the most fascinating and
prospective in regard to treating TRD. Rather than blocking the reuptake of serotonin as the class
of SSRIs do, or shocking brain regions to decrease regional brain neuronal reactivity as ECT
does, these drugs increase brain entropy, thereby producing more extensive and integrated
neuronal networks of reactivity. This increase in brain entropy can best be understood as a web
of connectivity that becomes denser with drug administration, producing the shifts in neuronal
activity marked by psychedelic compounds (Carhart-Harris et al., 2014). These transitions in
neuronal activity are evidence for the basis for shifts in mindsets and changes to an individual’s
ego throughout a session. Going deeper into the mechanisms of action, it appears psilocybin
works to mitigate cognitive dysfunctions implicated in depressive symptoms such as
over-arousal of the hippocampal and amygdala regions. During a treatment, psilocybin has been
shown to decrease amygdala activation while increasing prefrontal reactivity, thus
downregulating unconscious responses while enabling more responsivity related to critical
thinking regions. Most impressively, follow-up readings examining these same regions show
increased connectivity between prefrontal and amygdala regions, reinforcing the possibility that
the psilocybin therapeutic experience may re-integrate and re-formulate emotional reactivity
(Mertens et al., 2020).
Comparing the therapeutic benefits with the potential negative side effects of
psilocybin-assisted treatment vs. those of ECT, it seems the benefit:risk ratio is in favor of
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psilocybin therapy for the treatment of TRD. ECT works by stimulating neurons, essentially
resetting the nervous system; however, this is at the cost of dampening neuronal activity
following treatment and may result in serious adverse consequences on cognitive function such
as loss in short-term memory. In contrast, psilocybin promotes more connectivity among brain
regions while only decreasing reactivity in brain regions related to the negative depressive
symptoms such as rumination. Additionally, current trials examining psilocybin have reported no
significant side effects following the administration of therapy. While there has been more work
done in the field of ECT and thus extensive studies to pull from, the reemerging psychedelic
movement gives hope to a more representative and larger sample pool from which specific
determinations about the therapeutic index and possibilities of this drug can be ascertained.
Clinical Trials: Hope and Future Forecasting in Treatment-Resistant Depression
Populations
Lyons and Carhart-Harris conducted a clinical study in 2018 that investigated whether
classical psychedelics can positively affect symptoms associated with depression. This research
examined three elements considered to comprise the cognitive triad of depression: negative
attitude towards self, environment, and the future. These aspects are fundamental in supporting
the reasoning behind the use of psychedelics to enhance therapy. The medicinal properties of
psilocybin counteract each part of the cognitive triad as they promote increased optimism,
psychological well-being, trait openness, and life satisfaction in an enduring way (Lyons &
Carhart-Harris, 2018). Therefore, given the well-known associated effects of psilocybin therapy,
researchers suggest dosing individuals experiencing TRD to mitigate the cognitive triad of
depression in each category, thus promoting healthier mental states and future outlooks (Watts et
al., 2017).
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To investigate this hypothesis, Lyons and Carhart-Harris developed a methodology to
explore the effects of psilocybin on depression by pinpointing a specific part of the cognitive
triad, depressive future outlook, and observing the perception of this before and after undergoing
psilocybin treatment. The design included 15 patients experiencing symptoms of TRD and 15
control individuals with normal mental states. The patients were asked to complete a Beck
Depression Inventory (BDI) survey for depressive symptoms and a Prediction of Future Life
Events (POFLE) for cognitive biases before dosing. In developing a POFLE test baseline,
patients and controls were tasked with completing the survey and reporting back 30 days later on
the true occurrence of life events in the time period following the predictions made before
dosing. This methodology provided a pre-treatment variable of the patients’ and controls’
predictive states, and through these tests, researchers formulated the experiment basis by
showing that depressed individuals maintain a pessimistic bias on future life of events which is
actually inaccurate insofar as predicting is concerned. Therefore, researchers were hoping to
manipulate this variable through the use of psilocybin, shifting the negative bias via positive
substance integration; this was intended to enhance positive future thinking and promote a more
accurate forecast of life events. After the initial self-report period, including the BDI and
POFLE, patients were dosed during two sessions spread out over two weeks. After each session,
BDI assessments were made, and upon culmination of the second dosing, POFLE surveys were
given with the same 30-day response of true activity period following.
The null hypothesis of this study is that participants undergoing treatment for depression
through use of psilocybin will have the same negative bias and inaccurate future forecast as they
did before treatment. The research hypothesis suggests there will be differences in the accuracy
and bias associated with the future forecasting as measured by the POFLE in patients pre-dosing
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of psilocybin and post. It is interesting to note analyses were conducted on a predominately white
and male population, without much racial or gender variation.
Analyses of each of the six sections provide evidence supporting psilocybin treatment by
covering different measures of the treatments’ effectiveness, thus allowing for well-rounded
statistical analysis and strong support of the research hypothesis. These analyses contribute as
puzzle pieces to answer the larger question of whether or not psilocybin is effective in treating
the pessimistic outlook on life associated with TRD.
Dependent sample tests for POFLE post-psilocybin treatment provide the first piece of
evidence supporting the research hypothesis, as paired samples test for patients undergoing
treatment were significant at a .05 alpha level, thus allowing for a rejection of the null that
psilocybin has no effect on decreasing negative forecasting. The independent T-test showed the
pessimism bias of patients experiencing TRD decreased, as their forecasting post-treatment
shared no significant difference from the control group in predictive behavior; this finding
suggests that after undergoing psilocybin treatment, individuals with TRD have the same
predictive aptitude and selection of mentally healthy individuals represented by the control
group. While preceding analyses suggested the bias was seemingly reversed, researchers still
needed support for the hypothesis that TRD-affected individuals would have decreased negative,
more accurate future forecasting. Dependent sample tests were conducted comparing pre- and
post-treatment accuracy of future forecasts in TRD patients. The results were statistically
significant at a .05 alpha level, showing that post-treatment forecasts in treated individuals were
much more accurate than forecasting before treatment. In a final point on negative bias
elimination, researchers analyzed negative bias based on a self-report of a quantitative negative
one to positive one scale. In comparing baselines reports of TDR bias with post-treatment
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reports, the dependent samples T-test found significant differences in negative biases, as they
were much lower in the post-treatment group. Supporting further evidence of negative bias being
eliminated, results were compared to the control group via an independent sample test and no
significant difference between groups was demonstrated. The final section of correlation rounds
out the analyses by providing insight into possible treatment effects specific to depressive
symptoms. In comparing the BDI and bias scores, there was a strong correlation of the variables
suggesting that a drop in BDI reflects a similar drop in pessimism bias. Therefore, though not
explicitly stated, the way these analyses were conducted and ordered suggests that psilocybin
decreases depression-related symptoms (BDI metric), thus eliminating roots of what may be
causing negative bias and allowing for more accurate future forecasting. Specific inferences
drawn from the research included, “psilocybin with psychological support treatment model may
alleviate pessimism bias in depression, giving them a clearer and more accurate outlook on the
future” (Lyons & Carhart-Harris, 2018). This inference appears to be well-justified and validated
given significant findings in the data, and while not stated in conclusion, this study provided
important insight into underlying depressive mechanisms relieved as a result of the psilocybin
treatment applications.
Psilocybin Treatment for Anxiety and Demoralization in Advanced-Stage Cancer Patients
The overlap between anxiety and depression presents a potential opportunity for efficacy
in treating anxiety, especially in novel investigations related to psychedelics. With TRD patients,
the argument presented for the application of psychedelics stemmed largely from the fact that
this was a last-ditch effort of sorts; essentially, many other forms of treatment for TRD had been
exhausted, leading up to exploring trials with psilocybin. Notably, treatment with psilocybin for
this disorder defined by its treatment-resistant nature was extremely effective in acute and
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long-term settings, providing remission of depressive symptoms months after administration
(Carhart-Harris et al., 2016). Similar to how TRD researchers are working to explore any
potential therapeutic practices that may alleviate depressive symptomatology, late-stage cancer
clinicians have reached a similar point in the treatment of anxiety around the prospect of death,
with recent evaluation of psychedelic-assisted therapy.
Death anxiety in cancer patients is detrimental to treatment outcomes and coping with
physical and mental side effects associated with cancer. Current research into anxiety faced by
these patients points to demoralization as a critical factor behind why they experience existential
crises (Bovero et al., 2019). While demoralization may provide insight into the mechanisms
behind this form of anxiety, it also presents a potential avenue for promoting spiritual well-being
in subjects. In leveraging broader healing modalities beyond common medical prescriptions,
practices such as mindfulness and psychedelic-assisted therapy to provide a unique means of
treatment may be feasible through deconstructing thoughts that accentuate states of
demoralization such as death-related fears and existential crises.
The Ross et al. 2016 study examined processes surrounding administering psychedelic
treatment to cancer patients and its efficacy in this population. The researchers behind this study
conducted due diligence to provide repeated measures of both primary and secondary outcomes,
employing similar testing periods to observe changes in BDI like the Lyons & Carhart-Harris
experiment. The repeated measures provided data over several important time periods before and
after administration, as well as from long-term follow-ups almost six weeks later. These
measurements offer relevant primary and secondary results that could prove beneficial in
differentiating between acute and long-term benefits stemming from this treatment. Examples of
primary measures included inventories assessing depression and anxiety in cancer patients
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throughout the trials, while secondary measures involved more subjective criteria such as quality
of life, and spirituality (Ross et al., 2016). Information from these assessments help evaluate if
this treatment effectively decreases death anxiety, and the variety of measurements utilized
identify which components of this treatment act specifically on processes related to the initiation
and perpetuation of anxiety.
In this trial, subjects were screened for general criteria to assess cancer patients under the
DSM -IV based diagnostic Structured Clinical Interview (SCID) examination. In addition to
initial screenings, cardiovascular measures including blood pressure and heart rate were taken
throughout the study to assess physiological factors of treatment. This double-blind study
involved groups that received either psilocybin or niacin as a control depending on random
assignment. Dosing occurred on two separate dates, with each subject receiving synthetic
psilocybin (.3mg/kg) or niacin (250mg) in each session (Ross et al., 2016).
A simple equation is utilized to convert the dosing of synthetic psilocybin to that
comparable for naturally occurring psilocybin. First, it’s important to note psilocybin mushrooms
are predominantly composed of water; given this, on average, every 1g of dried mushrooms
results in approximately 5mg of psilocybin. For most psilocybin-containing mushrooms, potency
ranges from .4-.6% psilocybin in each mushroom. Therefore, for 1g at .5% potency, samples will
generate approximately 5mg of psilocybin per gram of mushroom. For reference, an individual
in the study weighing approximately 150 lb., or 66kg, would be given a dose of 20-25mg
psilocybin. This is equivalent to around five grams of dried mushroom, a significant dose most
clinicians would define as “heroic,” guaranteed to impart perspective shifts on even the strongest
of egos.
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Upon administration, participants become immersed in various emotions that stem from
the mystical experiences promoted by psychedelic drugs. In these engaging and sometimes
difficult experiences, subjects are reassured by clinicians to trust the safe environment procured
and surrender control, or let go. A strong element of this form of therapy is the dissolution of ego
and shifts of ingrained perception that result from the medicine. For example, a patient
experiencing death anxiety may be inundated with thoughts relating to their own existence,
impact on others, financials related to their looming death, etc. Psilocybin-assisted therapy often
forces a user to face these fears by removing themselves from future associations and becoming
grounded in the present. For someone dealing with debilitating anxiety stemming from fear of
the future, this therapy allows the individual to break ruminative patterns that may cloud
perception to form a more realistic perception of life.
While it may seem contradictory to suggest a mind-altering drug can assist in clearing
someone’s head, this contradiction is rooted in the stark contrast between the social perception of
these drugs with how they are utilized in a therapeutic space. For an individual entrenched in
their existing perspectives on life, a drug with the ability to eliminate – or even re-write – those
routes of thinking provides a possible path to rehabilitation not common to other psychiatric
pharmaceuticals. While other forms of treatment often focus on returning patients to “normalcy”
by merely treating symptoms, psychedelic-assisted therapy offers a rounded approach to
rehabilitation; this goes beyond eliminating symptomology via rewiring existing neural
pathways, thus providing hope through actualization. Through perceptive and emotional insights
induced by this medicine, subjects can transfer their demoralization into an understanding of the
self in a larger context that often promotes a sense of spirituality and connectedness.
Psychedelics offer a literal trip, and it is in this departure from thinking that the healing journey
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begins. It doesn't require a daily prescription or weekly sessions with a clinician. This form of
therapy strictly requires the patient to be open to change, as therapeutic outcomes are
significantly correlated with how the patient receives shifts in perception and integrates them
into their ways of thinking accordingly (Grob et al., 2011).
The focus of this study draws significance from decreases in the primary measures
associated with anxiety and depression, and secondary shifts in metrics relating to
demoralization and spirituality. Before and after each dosing session, subjects were assessed
using both primary and secondary measures. The results provided insight throughout the
therapeutic process to highlight when certain changes occurred and when effects related to
residual outcomes either digressed or disappeared entirely. In the Ross et al. 2016 study,
significant effects on both primary and secondary endpoints regarding psilocybin treatment were
observed. In the primary measures, clear reductions in depressive and anxious symptoms for
most participants – in both the acute administration of the drug and period following – were
exhibited with anti-depressant effects lasting up to the 26-week mark post-assessment.
Secondary outcomes found more gradual changes yet progressive, with spirituality and
connectedness significantly increasing and demoralization steadily decreasing throughout the
trials. Regardless of whether patients received the psilocybin dose in session number one or two,
each subject noted significant shifts in symptoms related to their death anxiety. In regards to
primary measures, 60-80% of all participants experienced a substantial reduction in symptoms.
Additionally, an astonishing 87% of patients noted greater life satisfaction on secondary
measures (Ross et al, 2016).
With significant results from these studies and many others, it becomes clear why the
FDA has recently granted psilocybin therapy with breakout therapy status (Saplakoglu, 2019).
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Most psilocybin research is currently being conducted within phase 2 clinical trials, meaning
most studies to date are to the point of providing this medicine to clinically affected populations.
Pending positive results, phase 3 trials to follow will work not only with clinical populations but
also larger representative samples. At this point, the future of psilocybin-assisted therapy rests on
the edge of further medicalization or regression into further clinical testing. Only time will tell
whether psilocybin will become a formidable therapeutic tool within the realm of treating mental
health.
Section 3: Lessons from Indigenous Psychedelic Practice
Chapter 5. Reverence to Ritual: How Set and Setting Reduce Negative Outcomes
One of the most significant concerns surrounding the use of psychedelics stems from the
idea that these substances have the potential to induce psychosis. Years of propaganda following
the Reagan administration convinced people hallucinogens could cause people to lose their
minds. This perception has since been perpetuated and is highlighted in social and media
portrayals surrounding psychedelic drugs, with exaggerated portrayals showing subjects under
the influence jumping out of windows, becoming constrained to psychiatric institutions, and even
harming others. While fear of psychosis has significantly affected how people generally perceive
psychedelics, studies examining adverse reactions to these drugs have reported that, in reality,
they rarely impart lasting negative side effects – with acute effects only being mildly adverse
(Van Amsterdamn et al., 2011). In the therapeutic setting, a general acute symptom that often
arises is anxiety, which often can be reduced and even mitigated with the assistance of a therapist
(Roseman, Nutt, Carhart-Harris et al. 2018).
In the clinical setting, research has shown that though anxiety may result from the
intensity of the psychedelic experience, controlling for set and setting can work to control
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anxiety and other negative symptomatology (Hartogsohn, 2017). The focus on set and setting
relative to drug use is not a new idea but was popularized by Timothy Leary in the 1960’s as he
sought to label subjects’ mind states and the environments in which a psychedelic experience
occurs. The idea of set refers to the individual’s mindset as they approach the experience,
encompassing aspects such as personality, expectations, and intentions going into and throughout
the therapeutic process. The setting has to do with the environment surrounding the individual
throughout the experience, which often includes the physical and social space as well as cultural
aspects. With the two variables of set and setting operating as major controls within the subjects’
experiences, it becomes necessary to distinguish how these objects may be controlled within the
clinical testing space.
Set is defined by qualities affecting the subject’s mental state going into the experience
and throughout the experience. By solidifying the subject’s set before the experience,
practitioners can develop a sense of alignment with the subject’s perspective going into the
treatment. Set preparation may include interviewing the patient weeks before the actual dosing,
assessing aspects of personality, and identifying intentions and expectations going into the
experience. During this preparation process, subjects are able to openly express fears and
anxieties regarding the upcoming therapeutic experience while receiving reassurance from
clinicians on safety. In addition, clarifications around any unwarranted expectations regarding
the therapy are provided. This process helps to decrease negative experiences, not necessarily by
eliminating these experiences themselves, but rather by preparing for and understanding them.
By allowing practitioners to assess fears before dosing, clinicians are better equipped to assess
anxiety-related reactions throughout treatment and apply remedies to decrease negative feelings
of anxiety accordingly. On the flip side, subjects can more comfortably express their previously
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mentioned fears if they arise in the session. Rather than being unprepared, therapists can use this
pre-built therapeutic alliance to provide care specific to each patient.
Specific to conditioning the set, it is important to consider how cultural differences might
explain differences in outcomes among patients undergoing this therapy. Anthony Wallace, a
cultural anthropologist studying differences in psychedelic experiences, explored this
phenomenon in his study, “Cultural determinants of response to hallucinatory experience”
(Hartogsohn, 2017). In this study, Wallace investigated the positive and negative experiences of
Whites and Native Americans consuming peyote, which generated interesting results. Wallace
found that White peyote users had less inhibition of sexual and aggressive behaviors, coupled
with mood swings ranging from anxiety, depression to euphoria, culminating in an exhibition of
psychiatric disorders ranging from paranoia to schizophrenia (Wallace, 1959). Native American
participants exhibited a much different reaction, maintaining more stable mental states
throughout the experience, religious awe regarding the hallucinatory experience, and better
integrating the experience into communal life (Wallace, 1959). An explanation for differences in
each experience seems to correlate to differences in racial background and the cultural context
from which the subjects originated. In White culture, hallucinations are often perceived as signs
of psychosis and are highly stigmatized, whereas in Native American culture, visionary
experiences are characterized as blessings beneficial for both the individual and the community
(Hartogsohn, 2017).
As we consider set relative to culture, it seems relevant to consider how culture, in turn,
affects aspects of set when preparing for a psychedelic experience. While expectations and fears
are accounted for in the initial screening process, how might aspects of culture be integrated into
study methodology to ensure that BIPOC individuals outside of the typical white sample
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populations have an equally therapeutic experience? The answer to this discrepancy requires the
integration of idiographic content within the experience while also composing culturally aligned
social support groups throughout the therapy session. By taking into mind fears and anxieties
that may stem from culturally relevant issues such as discrimination, personal trauma, and
generational trauma, it may be easier to pair clinicians with similar subjects. For example, rather
than pairing a Hispanic patient with a white clinician, who may not intimately understand the
relevant generational and social trauma associated with mental health, we may choose to pair this
subject with a culturally aware Black or Hispanic clinician (Asnaani and Hofmann, 2012).
Providing an array of clinicians from marginalized or minority groups for subjects from the same
groups, in turn, includes room for shared experiences that may offer higher levels of therapeutic
alliance.
In considering the set, we are also prompted to question how cultural differences may
arise in a controlled treatment environment or setting. In developing the second control of setting
for this form of therapy, it seems reasonable to suggest culture may help inform personalized
settings relative to the cultural makeup of the subject. For setting, the most essential aspects to
consider are the physical and social spaces the therapy occurs within. Physical aspects may
include elements such as the music played, art and statues within the room, and more specific
characteristics including lighting and couch layout. On the other hand, social aspects may
involve people present beyond the clinician that may serve to offer support and provide a
secluded environment free of interruption from random individuals. The way culture may help to
influence these physical and social components is by altering the composition of items and
individuals present in the therapeutic environment. For example, music and art that may add a
sense of welcome and comfortability for a white subject may differ for a Black patient. By
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providing culturally tasteful music, art, the comfort level of subjects with their environments will
likely increase, thereby opening the space to a deeper dive into the psychedelic experience
through an enhanced trust in setting. In respect to modifying social settings, it may be
appropriate, for example, for a Hispanic subject to have at least one BIPOC (Black, Indigenous
and people of color) individual present among the available members for social support. For
example, in considering Black usage of psychedelics, the literature explains:
African Americans who participate in broader psychedelic culture may not be free of
negative setting influences. Being a minority in a hyper-White space could exacerbate
feelings of double-consciousness, limit opportunities to confirm their identities, and
increase instances of identity disconfirmation (Neitzke-Spruill, 2020).
In a psychedelic-induced therapeutic experience, it is not uncommon for subjects to
unlock years of intergenerational trauma, which may be an experience that outgroup clinicians
may have increased difficulty relating to as well as assisting with. By providing a supportive
social setting composed of individuals who may be able to relate with shared experiences, the
subject can express themselves in a heard and better understood way.
Chapter 6. The Role of the Healer: Comparing Indigenous Healers to Clinicians
“Over 70% of all western drugs have come from isolating the active ingredients in plants and
animals that the world’s Indigenous people had already been using for medicinal purposes for
centuries...”
-A. Ross
While the above quote was stated in 1966 by researcher A. Ross, its relevancy is still as
applicable today as ever before. Examining set and setting only mark the beginning of the need
to evaluate extra-drug effects encompassed within psychedelic therapy. By controlling for set and
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setting, clinicians can assist subjects directly while also manipulating the environment to ensure
a better setting for the therapeutic process; therefore, the role of these clinicians must be greatly
examined as well. In considering the clinician’s influence in providing a profound therapeutic
experience, it sounds oddly similar to the perception we have of indigenous healers’ role in
traditional hallucinogenic ceremonies. However, in comparing clinical treatment to the
indigenous ceremony, there is one key difference: clinicians are working to produce a replicable
test environment. In contrast, healers work dynamically within a ritual framework to guide and
protect subjects within a manipulated setting.
Comparing traditional mushroom ceremonies to the clinical setting, there are also
apparent differences in how the user’s set is established. In the clinical environment, set is
framed through an intense interviewing process to develop a composite for the clinician to use
throughout treatment. In a traditional setting, healers are tasked with using their experience and
thorough understanding of the sacred mushroom to provide appropriate dosing, in addition to
providing discernment of whether or not the subject may participate in ceremony. In both
situations, it seems crucial for the individual in charge to screen participants for personality
attributes that may not be congruent with the goals of this form of therapy.
The traditional healer must rely on experience and cues, whereas a clinician has their
schooling accompanied with batteries of personality tests. Though traditional healers may lack
the professional resources therapeutically-approved assessments clinicians have at their disposal,
they often have more expertise identifying appropriate candidates for psilocybin therapy because
of their extensive experience performing the therapeutic rituals. Given the novel nature of
clinical trials for this type of therapy, it is reasonable to suggest that most clinicians working
within these studies have conducted fewer psychedelic ceremonies than traditional healers.
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Indigenous healers spend their entire lives specializing in the administration and refinement of
this form of therapy, engaging in training from as early as teenage years, if not earlier, to pass
down tradition and continue this calling from the sacred mushroom for the rest of their lives
(Lane, 2018). In an average year, it is common for these healers to be engaged in psychedelic
ceremonies 50-100 times a year (Lane, 2018), with roles ranging from serving as an active guide
partaking in the medicine to acting as additional support for the individuals in the space. In
comparing methods for discerning candidacy between clinicians and healers, clinicians may have
more thorough processes and tools at their disposal. In reality, the experience of a healer serves
an equally beneficial role as any personality test. In considering a traditional healer’s experience
as a viable tool for discernment, the importance of traditional ecological knowledge (TEK)
becomes apparent:
“More than a body of knowledge, TEK also encompasses such aspects as spiritual
experience and relationships with the land. It is a way of life, rather than being just the
knowledge of how to live, it is the actual living of that life” (McGregor, 2004).
Since clinicians in the US most commonly serve subjects in office, they are often able to remove
themselves from the test environment relatively easily. Meanwhile, traditional healers live within
their treatment environment, acting as active participants within the community while also
maintaining a relationship with nature and the medicine it provides. Lastly, in comparing the
establishment of the set following each unique treatment methodology, it is vital to recognize
differences in the integration of challenging experiences while on psychedelics, or ‘the bad trip.’
For clinicians, a subject's bad trip, often coupled with anxiety, may be quickly chalked up
to the presentation of adverse symptomatology, with remission of symptoms following the acute
state. The clinician may work with the subject to help them work through the negative
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symptomatology, yet usually to mitigate feelings rather than use them as points for reflection. In
contrast, healers often designate these distressing experiences as insightful posits or the
psychedelic journey that serve as lessons about oneself. It is these same experiences that, in turn,
provide avenues towards growth by addressing stuck points within the participant.
Often, sickness accompanies high doses of psilocybin, leading to bouts of vomiting and
purging, which may be reported as a negative physiological outcome in the clinical setting.
Again, contrasting with a clinician’s response, a traditional healer may symbolically attach
meaning to this experience by labeling it as purging evil toxins and spirits within the participant,
thus considering this experience to be beneficial. In comparing the methodology of both groups,
we must ask whether a trained clinician may employ traditional indigenous tactics and
perspectives to potentially enhance a user’s experience. Considering how healers deal with what
we perceive as adverse symptomatology, there is an opportunity to inform western science with
traditional ecological knowledge (TEK). Suppose clinicians could learn to perform tactics similar
to that of healers allowing for better integration of tough experiences. In that case, it may be
possible to solidify the cost-benefit ratio behind this form of therapy. The most significant
deterrent of psychedelic therapy’s progress stems from the stigmatization that perpetuated these
drugs’ danger, mainly based on bad trip experiences. Through adherence to insights from TEK
and controlling set and setting, it may be possible to decrease negative experiences associated
with these drugs by turning these experiences into opportunities through proper integration.
Since integration is an integral mechanism in psychedelic healing, it is essential to reflect
on how these experiences may be interpreted across different cultures by both the subject and
therapeutic leader. Bringing back to mind Wallace’s assessment of white and Native American
use of peyote presents an opportunity to compare how messages may face different forms of
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integration depending on the culture. Wallace found that white peyote users had a much higher
presentation of negative symptoms and increased issues with integration when compared to
Native Americans who experienced better therapeutic outcomes (Wallace, 1959). Wallace
explained that these differences stemmed from the fact that negative experiences such as
hallucinations and disembodiment in the respective cultures are starkly different. White culture
often classifies such an experience as bordering on psychosis, whereas Native Americans
cherished these aspects of a psychedelic journey with reverence, marking them as instances of
prophetic insight for the self and the larger community. In light of the cultural differences that
give way to differences in perception and experience, it seems necessary to conduct therapy to
represent cultural upbringing for appropriate, beneficial integration of experience. By providing
information regarding the true nature of the therapy, possibly coupling this information with
presentations from individuals who are well-versed in this form of medicine, we may produce
more open mindsets that may provide better outcomes for all.
Section 4: Prospects Regarding the Integration of Psychedelic Therapy into Mainstream
Practice
Chapter 7. Treatment Availability: A Medicine for the Rich?
While psychedelic medicine provides some wonderful prospects regarding therapeutic
benefits, the question of who will be able to afford this form of therapy remains in question.
Using MDMA and Ketamine clinics as a projectable model for the cost associated with
psychedelic-assisted therapy, we can highlight who realistically will be able to afford this form of
treatment. The total cost for a 12 week MDMA treatment ranges from 5,000-10,000 dollars per
dosing session, out-of-pocket (Stone, 2019). It is currently unclear whether or not insurance
policies will cover the costs of this form of treatment. Therefore the glaring cost for treatment
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poses a possible barrier for lower socioeconomic populations. This concern of access has already
been highlighted in phase 1 and 2 trials surrounding this medicine, even though costs to
participate in clinical trials are often non-existent, with most subjects receiving compensation for
their participation instead.
In assessing the racial diversity sampled within study populations, there lies an apparent
discrepancy among the different racial populations sampled in the studies. In a meta-analysis of
18 psychedelic studies from 1993-2017, researchers found that among 282 participants, 82.3% of
the participants were non-Hispanic white (Michaels, 2018). Considering recent census data that
has reported white individuals only comprise 60% of the population (Ghosh, 2021), this sample
exhibits the lack of comparability to the makeup of the US. Recognizing differences in those
tested begs the question, are current psychedelic trials accounting for variability in cultural
experience that may affect therapeutic outcomes? Furthermore, if access to this treatment is
limited to only those that can afford one thousand dollar treatments, will this highly efficacious
form of therapy ever reach the marginalized communities that need better mental health
treatment?
Despite recent advancements in psychedelic research and associated therapeutic
applications, work still needs to be done in future clinical studies to diversify sample populations
selected for future study. If psilocybin progresses past phase 3 into medicalization, it seems
necessary to consider how this form of treatment could become fully accessible throughout the
socio-economic and racial spectrum. Whether through scholarships, expanded clinical trials, or
stronger recruiting efforts, there is a clear need to decrease the gap in the availability of this
treatment. In doing so, psychedelic researchers will be able to provide more realistic projections
on the differences in therapeutic outcomes across different populations. Beyond test data,
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considering the breakthrough status of this drug, it is only equitable that this treatment is made
available for affluent white subjects and any individual meeting requirements for treatment. By
providing this novel form of therapy to a larger audience, psychedelic treatment may serve to
help unpack years of trauma and discrimination that weighs heavy on the minds of many
marginalized groups.
Chapter 8. Bridging the Gap: Using Psychedelic Medicine to Promote Cultural Inclusiveness
and Diverse Clinicians to Counteract Racial Disparities in Mental Health
Though there are clear differences in the racial groups receiving this treatment, the
development of more culturally reflective forms of therapy provides an avenue toward equitable
healthcare across racial categories. In order to develop a more culturally inclusive space, three
essential dynamics must be addressed in the formulation of future psychedelic healing
modalities; these considerations are culturally inclusive settings, diverse clinicians, and
implementation of different social dynamics that should encompass the future standards of this
practice.
While culturally inclusive settings have been extensively discussed in this review, this
aspect of effective treatment ranges beyond the clinical environment into our social settings.
Considering that 80% of the individuals sampled in studies have been white, it's almost as if safe
spaces for the consumption of psychedelic substances have been exclusively procured for this
group to date. Through the safety of the medical setting, participants are absolved from
repercussions that may stem from local officials if one were to consume these drugs in a public
setting. Minority groups, not prevalently privy to such studies and thus left to resort to taking
these substances in their own social spaces, may not have the same protections as those in the
clinic – thus furthering the concerns regarding safety and support for these minority groups
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(Neitzke-Spruill, 2020) . In an effort to relinquish inequities, further work should be done to
provide safe spaces for consuming these substances for different racial groups with idiographic
components that align with the participant’s associated culture. Rather than ascribing to novel
ideas regarding the development of these settings, it may be possible to draw from indigenous
knowledge regarding these ceremonies.
Considering the role traditional ceremonies could play in informing clinical practice on
the development of safe spaces, the individuals responsible for conducting the ceremonies, the
curandero/as, may be beneficial in guiding clinicians. In reflecting on the root of traditional
practices in indigenous communities, the mechanisms for development of these practices seem to
stem from the following:
“The stories and testimonies of Indigenous peoples are usually related to a home place or
territory. TEK embodies both remembered sensory information built upon repeated
observation, and formal understandings that are usually transmitted orally in story form
or ceremonial form with abstract principles and important information encapsulated in
metaphor” (Cruikshank, 1991).
In the development of idiographic settings, it seems necessary to include culturally relevant
themes and components of setting that provide a sense of home and solidarity within the space. It
is also essential to include diverse clinicians, if possible native healers, to aid in integrating
processes in a culturally reflective manner. In doing so, it seems possible to detach
psychedelic-assisted therapy from the air of institutionalization to a more relatable setting of
traditional ceremony that may even be in greater cultural alignment for Hispanic and more
comfortable for other BIPOC participants.
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Though we may be able to produce a diverse and thus more open space for therapy, it
doesn't change the fact that mental health treatment, in general, is a financial burden not all can
afford. Group therapy provides a two-punch approach to the issue of accessibility as well as
cultural inclusivity. Allowing clinicians to treat more than one individual at a time while also
including multiple individuals in the treatment space serves to produce a diversity of experiences
that may be shared among participants. For example, a group therapy study conducted in 2020
on demoralized long-term AIDS survivors (11 White, 3 Black, and 2 Hispanic) found “several
participants reported they were able to connect quickly with the other group members and that
this peer support was helpful in tolerating and making use of the intervention” (Anderson et al.,
2020, Pg. 7). The ability of group members to build rapport among one another, independently of
alliances with clinicians, therein lies the potential for the development of group retreat settings
that mimic this study to provide reciprocal support systems for a diverse array of participants.
Although group therapy is a step in the right direction to decrease costs associated with
psychedelic-assisted therapy, access must extend to communities that can hardly afford current
forms of mental health treatment. On a meta-scale, by performing group therapy with fewer
clinicians than would be required for individualized sessions, additional therapists will be
available to treat other new patients (Rosner, 2020). Also, success rates of psychedelic-assisted
therapies serve to mitigate the need for future continuous mental health treatment, thus
decreasing the accumulating cost of treatment for the individual while equally decreasing strain
on the mental health system. Projections from studies on MDMA reported, “for every 1,000
patients treated, we estimate 30-year savings to the medical care system of $103 million, while
averting 42.9 deaths. The finding of net savings holds across a wide range of plausible
assumptions and input values” (Marseille et al., 2020, Pg. 10). These future projections in
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regards to MDMA-assisted therapy alleviating financial stress on the mental healthcare system
allow us to consider the potential impact of concurrently run studies utilizing MDMA, Ketamine,
and Psilocybin; as such, these therapies may together work to decrease financial costs within the
institution that can be reallocated to less fortunate groups in need of treatment.
Conclusion
While there is much work to be done across various realms within psychedelic science,
the future remains bright, full of possibility, and ripe with opportunities for healing. Only time
will tell if these treatments have the potential to spread among different racial and socioeconomic
demographics effectively, but for now, the medical psychedelic space in the United States is
dominated by the experiences of white clinicians and participants. With the legalization of
psychedelic-assisted therapy in Oregon, we see another spark of hope regarding the diversifying
of clinicians, given the reasonably low barrier for entry in regard to receiving certification to
perform therapy. Specifically, the omission of requiring higher education demonstrates
inclusivity and mindfulness that some of the most experienced practitioners in this realm may not
be accredited with Ph.D.s or M.D.s but rather have decades of experience serving as indigenous
healers conducting ceremonial healings with magic mushrooms. Decriminalization efforts help
add protections for individuals who may not be able to afford the set, setting, and safety provided
by a clinical setting. These considerations around therapeutic accessibility and applicability
between white and minority individuals, in addition to decriminalization efforts, serve to
eliminate fears of repercussions from local officials that may affect the setting for these
individuals' experience. Only through further efforts to actively rewrite the surrounding narrative
psychedelics and associated treatments may we enter into a future in which psychedelic
ceremony is no longer a stigmatized experience but rather a recognized therapy – for those in
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need in of healing, in search of creative expansion, or even suburban parents curious about
exploring the depths of human consciousness and existence.
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